Rheumatologist's preferences for a treatment choice in a patient with moderate and high disease activity
| Patient profile | Moderate disease activity | High disease activity | |||
| Attributes and levels | Estimate (95% CI) | Relative contribution of attributes | Estimate (95% CI) | Relative contribution of attributes | Comparison between patient profiles (p Value) |
| Efficacy | 47.7% | 56.9% | |||
| Moderate response | Reference level | Reference level | |||
| Good response | 1.57* (0.92 to 2.22) | 1.97* (1.17 to 2.77) | 0.02 | ||
| Remission | 2.77* (1.70 to 3.85) | 3.25* (2.00 to 4.51) | 0.01 | ||
| Safety | 12.9% | 11.2% | |||
| Very rare | Reference level | Reference level | |||
| Rare | −0.32† (−0.69 to 0.05) | −0.29 (−0.71 to 0.13) | 0.62 | ||
| Uncommon | −0.75* (−1.22 to −0.29) | −0.64‡(−1.14 to −0.14) | 0.34 | ||
| Patient's preference | 15.0% | 10.7% | |||
| Treatment favoured | 0.46* (0.20 to 0.71) | 0.51* (0.24 to 0.78) | 0.63 | ||
| Patient is neutral | Reference level | Reference level | |||
| Treatment disfavoured | −0.41* (−0.62 to −0.20) | −0.10 (−0.29 to 0.10) | 0.03 | ||
| Cost-effectiveness (10 000 EUR/QALY) | −0.10* (−0.16 to −0.04) | 10.3% | −0.07‡ (−0.12 to −0.01) | 7.4% | 0.15 |
| Overall medication costs (1000 EUR/year) | −0.06* (−0.09 to −0.04) | 14.1% | −0.06* (−0.09 to −0.03) | 13.8% | 0.82 |
| Constant | −0.12 (−0.62 to 0.38) | −0.18 (−0.78 to 0.42) | |||
In bold: Significant (significant at ≤5%) heteroscedasticity in preferences when changing disease severity of patient.
*Significant at 1%.
†Significant at 10%.
‡ Significant at 5%.
QALY, quality-adjusted life year.